Novo Nordisk Ozempic sales expected to reach $17B in 2029


Demand Surges For Weight Loss Drug Ozempic

Mario Tama/Getty Images News

Ozempic, Novo Nordisk’s (NVO) best-selling drug, will achieve annual sales of $17B by 2029 as it will continue its dominance in the diabetes market, according to a new report.

Data analytics and consulting company GlobalData expects Ozempic (semaglutide) sales to rise 23% in

Source link

Leave A Reply

Your email address will not be published.